JRVR vs RILY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JRVR presents a classic 'value trap' profile, characterized by a very weak Piotroski F-Score of 2/9 indicating deteriorating fundamental health. While the stock is significantly undervalued on a Price-to-Book (0.53) and Graham Number ($14.79) basis, this discount is justified by extreme earnings volatility and a history of massive quarterly misses. Strong top-line revenue growth of 32.4% is offset by an unstable bottom line and poor operational health scores. The current price of $6.20 sits near the growth-based intrinsic value, suggesting limited upside until financial stability is proven.
RILY exhibits severe financial instability, highlighted by a weak Piotroski F-Score of 2/9 and a critical negative Price-to-Book ratio of -0.92, indicating negative shareholders' equity. While the P/E ratio of 1.04 and high YoY revenue growth (75.8%) appear attractive on the surface, they are likely value traps given the company's erratic earnings history and lack of fundamental health. The absence of an Altman Z-Score and Graham Number further underscores the inability to apply standard valuation models to this distressed balance sheet. Despite a recent 1-year price surge, the long-term trend is deeply negative, and the financial foundation is precarious.
Compare Another Pair
Related Comparisons
JRVR vs RILY: Head-to-Head Comparison
This page compares James River Group Holdings, Inc. (JRVR) and BRC Group Holdings, Inc. (RILY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.